SUVENHealthcare Research, Analytics & Technology
Suven Life Sciences Ltd — Profit & Loss Statement
₹131.70
-2.75%
Suven Life Sciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.11 Cr | 0.00 | 0.00 |
| Tax Rate For Calcs | 0.00 | 0.01 | 0.00 | 0.00 |
| Normalized EBITDA | -159.85 Cr | -111.44 Cr | -119.40 Cr | -121.06 Cr |
| Total Unusual Items | 4.98 Cr | 12.02 Cr | 7.96 Cr | 3.99 Cr |
| Total Unusual Items Excluding Goodwill | 4.98 Cr | 12.02 Cr | 7.96 Cr | 3.99 Cr |
| Net Income From Continuing Operation Net Minority Interest | -160.75 Cr | -105.08 Cr | -118.27 Cr | -122.00 Cr |
| Reconciled Depreciation | 5.31 Cr | 5.82 Cr | 5.83 Cr | 3.56 Cr |
| Reconciled Cost Of Revenue | 1.04 Cr | 0.72 Cr | 0.37 Cr | 0.16 Cr |
| EBITDA | -154.88 Cr | -99.42 Cr | -111.44 Cr | -117.07 Cr |
| EBIT | -160.70 Cr | -105.92 Cr | -117.98 Cr | -121.46 Cr |
| Net Interest Income | 5.52 Cr | 16.13 Cr | 6.00 Cr | 0.46 Cr |
| Interest Expense | 0.05 Cr | 0.16 Cr | 0.29 Cr | 0.53 Cr |
| Interest Income | 5.68 Cr | 16.43 Cr | 6.42 Cr | 1.13 Cr |
| Normalized Income | -165.72 Cr | -116.98 Cr | -126.23 Cr | -125.98 Cr |
| Net Income From Continuing And Discontinued Operation | -160.75 Cr | -105.08 Cr | -118.27 Cr | -122.00 Cr |
| Total Expenses | 177.90 Cr | 145.99 Cr | 145.46 Cr | 137.92 Cr |
| Rent Expense Supplemental | 0.29 Cr | 0.04 Cr | 0.00 | 0.00 |
| Diluted Average Shares | 21.81 Cr | 21.81 Cr | 21.81 Cr | 13.48 Cr |
| Basic Average Shares | 21.81 Cr | 21.81 Cr | 21.81 Cr | 13.48 Cr |
| Diluted EPS | -7.37 | -4.82 | -6.63 | -9.05 |
| Basic EPS | -7.37 | -4.82 | -6.63 | -9.05 |
| Diluted NI Availto Com Stockholders | -160.75 Cr | -105.08 Cr | -118.27 Cr | -122.00 Cr |
| Net Income Common Stockholders | -160.75 Cr | -105.08 Cr | -118.27 Cr | -122.00 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -160.75 Cr | -105.08 Cr | -118.27 Cr | -122.00 Cr |
| Net Income Including Noncontrolling Interests | -160.75 Cr | -105.08 Cr | -118.27 Cr | -122.00 Cr |
| Net Income Continuous Operations | -160.75 Cr | -105.08 Cr | -118.27 Cr | -122.00 Cr |
| Tax Provision | 0.00 | -1.00 Cr | 0.00 | 0.00 |
| Pretax Income | -160.75 Cr | -106.08 Cr | -118.27 Cr | -122.00 Cr |
| Other Non Operating Income Expenses | 0.24 Cr | 0.14 Cr | 0.01 Cr | 0.01 Cr |
| Special Income Charges | 0.00 | 7.47 Cr | 6.17 Cr | 3.63 Cr |
| Net Non Operating Interest Income Expense | 5.52 Cr | 16.13 Cr | 6.00 Cr | 0.46 Cr |
| Total Other Finance Cost | 0.12 Cr | 0.14 Cr | 0.12 Cr | 0.14 Cr |
| Interest Expense Non Operating | 0.05 Cr | 0.16 Cr | 0.29 Cr | 0.53 Cr |
| Interest Income Non Operating | 5.68 Cr | 16.43 Cr | 6.42 Cr | 1.13 Cr |
| Operating Income | -171.25 Cr | -134.30 Cr | -131.92 Cr | -126.08 Cr |
| Operating Expense | 176.87 Cr | 145.27 Cr | 145.09 Cr | 137.76 Cr |
| Other Operating Expenses | 3.33 Cr | 2.61 Cr | 1.85 Cr | 3.46 Cr |
| Depreciation And Amortization In Income Statement | 5.82 Cr | 6.50 Cr | 6.54 Cr | 4.39 Cr |
| Amortization | 0.03 Cr | 0.03 Cr | 0.03 Cr | 0.02 Cr |
| Depreciation Income Statement | 5.79 Cr | 6.47 Cr | 6.52 Cr | 4.37 Cr |
| Research And Development | 143.96 Cr | 114.43 Cr | 115.35 Cr | 106.37 Cr |
| Selling General And Administration | 2.64 Cr | 2.71 Cr | 2.78 Cr | 2.49 Cr |
| General And Administrative Expense | 2.64 Cr | 2.71 Cr | 2.78 Cr | 2.49 Cr |
| Rent And Landing Fees | 0.29 Cr | 0.04 Cr | 0.00 | 0.00 |
| Gross Profit | 5.62 Cr | 10.98 Cr | 13.17 Cr | 11.68 Cr |
| Cost Of Revenue | 1.04 Cr | 0.72 Cr | 0.37 Cr | 0.16 Cr |
| Total Revenue | 6.66 Cr | 11.69 Cr | 13.54 Cr | 11.84 Cr |
| Operating Revenue | 6.66 Cr | 11.69 Cr | 13.54 Cr | 11.84 Cr |
| Other Special Charges | — | -7.47 Cr | -6.17 Cr | -3.63 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Suven Life Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.